Rigel Pharmaceuticals Inc. logo

Rigel Pharmaceuticals Inc. (RIGL)

Market Closed
6 Jun, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
21. 50
+0.53
+2.53%
$
367.1M Market Cap
- P/E Ratio
0% Div Yield
182,100 Volume
-0.06 Eps
$ 20.97
Previous Close
Day Range
21.18 21.86
Year Range
7.48 29.82

Summary

RIGL closed today higher at $21.5, an increase of 2.53% from yesterday's close, completing a monthly increase of 10.26% or $2. Over the past 12 months, RIGL stock gained 26.47%.
RIGL is not paying dividends to its shareholders.
The last earnings report, released on May 05, 2025, exceeded the consensus estimates by 0.54%. On average, the company has surpassed earnings expectations by 0.25%, based on the last three reports.
Rigel Pharmaceuticals Inc. has completed 2 stock splits, with the recent split occurring on Jun 27, 2024.
The company's stock is traded on 3 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).
Want to track RIGL and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

RIGL Chart

Chart

Empty chart
The chart has 2 Y axes displaying values, and values.
Loading, please wait...
End of interactive chart.
Is Rigel Pharmaceuticals (RIGL) Stock Undervalued Right Now?

Is Rigel Pharmaceuticals (RIGL) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks | 1 week ago
Wall Street Analysts See a 71.97% Upside in Rigel (RIGL): Can the Stock Really Move This High?

Wall Street Analysts See a 71.97% Upside in Rigel (RIGL): Can the Stock Really Move This High?

The consensus price target hints at a 72% upside potential for Rigel (RIGL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks | 1 week ago
Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress

Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress

Final data from the GAVRETO® (pralsetinib) Phase 1/2 ARROW study in RET fusion-positive NSCLC and other solid tumors   Supportive data for REZLIDHIA® (olutasidenib) utilization in patients with mIDH1 R/R AML SOUTH SAN FRANCISCO, Calif. , May 22, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced seven upcoming poster presentations at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) 2025 Congress.

Prnewswire | 2 weeks ago

Rigel Pharmaceuticals Inc. Dividends

RIGL is not paying dividends to its shareholders.

Rigel Pharmaceuticals Inc. Earnings

5 May 2025 Date
0.09
Cons. EPS
0.63
EPS
4 Mar 2025 Date
0.58
Cons. EPS
0.8
EPS
3 Mar 2025 Date
-
Cons. EPS
-
EPS
7 Nov 2024 Date
0.06
Cons. EPS
0.7
EPS
5 Nov 2024 Date
0.06
Cons. EPS
-
EPS
RIGL is not paying dividends to its shareholders.
5 May 2025 Date
0.09
Cons. EPS
0.63
EPS
4 Mar 2025 Date
0.58
Cons. EPS
0.8
EPS
3 Mar 2025 Date
-
Cons. EPS
-
EPS
7 Nov 2024 Date
0.06
Cons. EPS
0.7
EPS
5 Nov 2024 Date
0.06
Cons. EPS
-
EPS

Rigel Pharmaceuticals Inc. (RIGL) FAQ

What is the stock price today?

The current price is $21.50.

On which exchange is it traded?

Rigel Pharmaceuticals Inc. is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is RIGL.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 367.1M.

Has Rigel Pharmaceuticals Inc. ever had a stock split?

Rigel Pharmaceuticals Inc. had 2 splits and the recent split was on Jun 27, 2024.

Rigel Pharmaceuticals Inc. Profile

Biotechnology Industry
Healthcare Sector
Mr. Raul R. Rodriguez CEO
NASDAQ (NGS) Exchange
766559702 Cusip
US Country
162 Employees
- Last Dividend
27 Jun 2024 Last Split
29 Nov 2000 IPO Date

Overview

Rigel Pharmaceuticals, Inc. is a forward-thinking biotechnology company deeply engaged in the discovery, development, and provision of innovative therapies aimed at improving the lives of patients dealing with hematologic disorders and cancer. Originating in 1996 and based out of South San Francisco, California, Rigel Pharmaceuticals has cemented its position in the biotech industry by focusing on cutting-edge research and strategic collaborations with key institutions such as The University of Texas MD Anderson Cancer Center. The company's pursuit of novel therapeutic solutions encompasses a robust pipeline of clinical and preclinical programs designed to address unmet medical needs in autoimmunity, cancer, and hematologic conditions.

Products and Services

  • Tavalisse
  • An oral spleen tyrosine kinase inhibitor specifically formulated for adult patients suffering from chronic immune thrombocytopenia (ITP). This innovative treatment represents Rigel's commitment to enhancing the quality of life for patients contending with this challenging autoimmune condition.

  • Rezlidhia
  • A groundbreaking, non-intensive monotherapy designed for adult patients with relapsed or refractory acute myeloid leukemia (AML) exhibiting a susceptible isocitrate dehydrogenase-1 (IDH1) mutation, as confirmed by an FDA-approved test. Rezlidhia underscores Rigel's focus on addressing critical gaps in cancer care, offering hope to those battling this formidable disease.

  • GAVRETO
  • A once-daily, orally administered small molecule kinase inhibitor targeted at adult patients with metastatic RET fusion-positive non-small cell lung cancer, as well as adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. GAVRETO exemplifies Rigel's precision in developing treatments that target specific genetic markers, paving the way for personalized medicine in oncology.

  • R289 (Oral IRAK1/4 Inhibitor)
  • Currently in Phase 1b clinical trials, R289 is an oral IRAK1/4 Inhibitor being explored for its potential in treating a range of conditions, including hematology-oncology, autoimmune, and inflammatory diseases. This investigational compound reflects Rigel's dedication to exploring new frontiers in medicine to combat a broad spectrum of diseases.

  • RIPK1 Inhibitor Program
  • Part of a collaborative effort with Eli Lilly and Company, this program focuses on the development of a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, highlighting Rigel's strategy of partnering with industry leaders to accelerate the development of innovative therapies.

Furthermore, Rigel's dynamic approach to drug development includes strategic alliances with BerGenBio ASA and Daiichi Sankyo, through which it advances additional product candidates into clinical development, reinforcing its commitment to bringing transformative treatments to market.

Contact Information

Address: 1180 Veterans Boulevard
Phone: 650 624 1100